Victoza: Manufacturer confirms discontinuation of type 2 diabetes mellitus treatment Victoza

Novo Nordisk has confirmed that its Victoza (liraglutide) 6mg/mL pre-filled injection pens have been discontinued. The pens, used in the treatment of type 2 diabetes mellitus (T2DM), have been out of stock in the UK since August 2023, having experienced supply issues along with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) since June 2023. In [...]The post Manufacturer confirms discontinuation of type 2 diabetes mellitus treatment Victoza appeared first on The Pharmaceutical Journal.